Literature DB >> 20395290

HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.

Xin Wang1, Abraham Schneider.   

Abstract

Despite their individual key roles in promoting head and neck squamous cell carcinoma (HNSCC) progression and treatment resistance, little is known about the impact of intratumoral hypoxia on the activity of the epidermal growth factor receptor (EGFR) signaling pathway in this cancer type. Here, we show that in highly EGFR-expressing HNSCC cells, hypoxic stress triggers the activation of the EGFR and downstream targets, including Akt and phospholipase C (PLC) gamma1. In support of these findings, we also demonstrate that EGFR activation takes place within hypoxic foci in a subset of human HNSCC tissues. Whereas hypoxia had no major effect on HNSCC cell proliferation, it markedly altered tumor cell shape by inducing morphological changes consistent with a more spindle-shaped, fibroblast-like morphology together with an enhanced migratory capacity. We found that hypoxia-induced EGFR activation and cell migration could be prevented by targeting EGFR signaling with the tyrosine kinase inhibitor tyrphostin, the phospholipase C inhibitor U73122, or by inhibiting the expression of the alpha subunit of hypoxia-inducible factor 2 via RNA interference or the topoisomerase II inhibitor etoposide. Our results position hypoxia-inducible factor-2alpha as a novel regulator of EGFR activation under low oxygen conditions, and suggest that hypoxia-induced EGFR signaling may promote a more aggressive phenotype in a fraction of HNSCC tumors. Because EGFR continues in the forefront as a highly attractive target in clinical oncology, further studies are warranted to define the mechanistic and therapeutic implications of the hypoxic response relative to the EGFR signaling pathway in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395290      PMCID: PMC2893799          DOI: 10.1093/carcin/bgq078

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  46 in total

1.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.

Authors:  D M Aebersold; P Burri; K T Beer; J Laissue; V Djonov; R H Greiner; G L Semenza
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 2.  Phospholipase C-gamma1 in tumor progression.

Authors:  Alan Wells; Jennifer Rubin Grandis
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

Authors:  Sufi Mary Thomas; Francesca M Coppelli; Alan Wells; William E Gooding; John Song; Jareer Kassis; Stephanie D Drenning; Jennifer Rubin Grandis
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

4.  Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.

Authors:  Virote Sriuranpong; Jong In Park; Panomwat Amornphimoltham; Vyomesh Patel; Barry D Nelkin; J Silvio Gutkind
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

5.  Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Authors:  Lakshman Gunaratnam; Melissa Morley; Aleksandra Franovic; Natalie de Paulsen; Karim Mekhail; Doris A E Parolin; Eijiro Nakamura; Ian A J Lorimer; Stephen Lee
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

6.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

Authors:  Bhavna Kumar; Kitrina G Cordell; Julia S Lee; Francis P Worden; Mark E Prince; Huong H Tran; Gregory T Wolf; Susan G Urba; Douglas B Chepeha; Theodoros N Teknos; Avraham Eisbruch; Christina I Tsien; Jeremy M G Taylor; Nisha J D'Silva; Kun Yang; David M Kurnit; Joshua A Bauer; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

Review 7.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

8.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

Authors:  David Lando; Daniel J Peet; Jeffrey J Gorman; Dean A Whelan; Murray L Whitelaw; Richard K Bruick
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

9.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.

Authors:  Cheng-Jun Hu; Li-Yi Wang; Lewis A Chodosh; Brian Keith; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.

Authors:  Annamaria Rapisarda; Badarch Uranchimeg; Olivier Sordet; Yves Pommier; Robert H Shoemaker; Giovanni Melillo
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  24 in total

1.  Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

Authors:  M Ahmadi; Z Ahmadihosseini; S J Allison; S Begum; K Rockley; M Sadiq; S Chintamaneni; R Lokwani; N Hughes; R M Phillips
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.

Authors:  Susan Richter; Nan Qin; Karel Pacak; Graeme Eisenhofer
Journal:  Adv Pharmacol       Date:  2013

Review 3.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

4.  Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells.

Authors:  Barbara Chiavarina; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Herbert B Tanowitz; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

Review 5.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

6.  HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.

Authors:  Sadeesh K Ramakrishnan; Huabing Zhang; Shogo Takahashi; Brook Centofanti; Sarvesh Periyasamy; Kevin Weisz; Zheng Chen; Michael D Uhler; Liangyou Rui; Frank J Gonzalez; Yatrik M Shah
Journal:  Cell Metab       Date:  2016-02-04       Impact factor: 27.287

7.  Functional organic cation transporters mediate osteogenic response to metformin in human umbilical cord mesenchymal stromal cells.

Authors:  Faisal E Al Jofi; Tao Ma; Dong Guo; Monica P Schneider; Yan Shu; Hockin H K Xu; Abraham Schneider
Journal:  Cytotherapy       Date:  2018-03-16       Impact factor: 5.414

8.  Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.

Authors:  R J Young; A Gupta; A D Shah; J J Graber; A D Schweitzer; A Prager; W Shi; Z Zhang; J Huse; A M P Omuro
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-27       Impact factor: 3.825

9.  Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.

Authors:  Carmen Muñoz; Miguel Caballero; Sofia Hakim; Eugenia Verger; Juan Jose Grau
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-06       Impact factor: 2.503

10.  Nicotine induces oral dysplastic keratinocyte migration via fatty acid synthase-dependent epidermal growth factor receptor activation.

Authors:  David J Wisniewski; Tao Ma; Abraham Schneider
Journal:  Exp Cell Res       Date:  2018-06-30       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.